Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban

  • Graeme J. Hankey
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Susanna R. Stevens
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Jonathan P. Piccini
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Yuliya Lokhnygina
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Kenneth W. Mahaffey
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Jonathan L. Halperin
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Manesh R. Patel
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Günter Breithardt
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Daniel E. Singer
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Richard C. Becker
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Scott D. Berkowitz
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • John F. Paolini
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Christopher C. Nessel
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Werner Hacke
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Keith A.A. Fox
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...
  • Robert M. Califf
    From the School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia (G.J.H.); Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia (G.J.H.); Duke Clinical Research Institute (S.R.S., J.P.P., Y.L., M.R.P.) and Duke Translational Medicine Institute (R.M.C.), Duke University Medical Center, Durham, NC; Department of Medicine, Stanford University, CA (K.W.M.); Cardiovascular Institute, Mount Sinai Medical Center, New York (J.L.H.); Department of...

書誌事項

タイトル別名
  • The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation

抄録

<jats:sec> <jats:title>Background and Purpose—</jats:title> <jats:p>Intracranial hemorrhage (ICH) is a life-threatening complication of anticoagulation.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods—</jats:title> <jats:p>We investigated the rate, outcomes, and predictors of ICH in 14 264 patients with atrial fibrillation from Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Cox proportional hazards modeling was used.</jats:p> </jats:sec> <jats:sec> <jats:title>Results—</jats:title> <jats:p> During 1.94 years (median) of follow-up, 172 patients (1.2%) experienced 175 ICH events at a rate of 0.67% per year. The significant, independent predictors of ICH were race (Asian: hazard ratio, 2.02; 95% CI, 1.39–2.94; black: hazard ratio, 3.25; 95% CI, 1.43–7.41), age (1.35; 1.13–1.63 per 10-year increase), reduced serum albumin (1.39; 1.12–1.73 per 0.5 g/dL decrease), reduced platelet count below 210×10 <jats:sup>9</jats:sup> /L (1.08; 1.02–1.13 per 10×10 <jats:sup>9</jats:sup> /L decrease), previous stroke or transient ischemic attack (1.42; 1.02–1.96), and increased diastolic blood pressure (1.17; 1.01–1.36 per 10 mm Hg increase). Predictors of a reduced risk of ICH were randomization to rivaroxaban (0.60; 0.44–0.82) and history of congestive heart failure (0.65; 0.47–0.89). The ability of the model to discriminate individuals with and without ICH was good ( <jats:italic>C</jats:italic> -index, 0.69; 95% CI, 0.64–0.73). </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions—</jats:title> <jats:p>Among patients with atrial fibrillation treated with anticoagulation, the risk of ICH was higher among Asians, blacks, the elderly, and in those with previous stroke or transient ischemic attack, increased diastolic blood pressure, and reduced platelet count or serum albumin at baseline. The risk of ICH was significantly lower in patients with heart failure and in those who were randomized to rivaroxaban instead of warfarin. The external validity of these findings requires testing in other atrial fibrillation populations.</jats:p> </jats:sec>

収録刊行物

  • Stroke

    Stroke 45 (5), 1304-1312, 2014-05

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (7)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ